Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Current pharmaceutical design

Showing results (121-130 of 10,653) with videos related to

Pageof 1,066
Sort By:
Current Pharmaceutical Design|July 7, 2015
Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU EnvironmentCarlos J Madrid-Navarro, Rosa Sanchez-Galvez, Antonio Martinez-Nicolas, et al.
Current Pharmaceutical Design|July 7, 2015
Disruption of Circadian Rhythms in Critical Illness - A Role of Hyperoxia-Induced Lung InjuryAlexander Czachor, Zachary Krueger, Young Cho, et al.
Current Pharmaceutical Design|July 7, 2015
Disruption of Circadian Rhythms and Sleep in Critical Illness and its Impact on Innate ImmunityViola Dengler, Kristin Westphalen, Michael Koeppen
Current Pharmaceutical Design|June 2, 2015
Multifunctional Delivery Systems for Advanced oral Uptake of Peptide/Protein DrugsJin Woo Park, Sun Jin Kim, Dong Sup Kwag, et al.
Current Pharmaceutical Design|June 6, 2015
Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?Bart A Ellenbroek, Bibinaz Ghiabi
Current Pharmaceutical Design|June 20, 2015
Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of Schizophrenia. Current Evidence and Future DirectionsMarine Mondino, Jerome Brunelin, Ulrich Palm, et al.
Current Pharmaceutical Design|June 20, 2015
Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous SystemGary Hulse, Erin Kelty, Sean Hood, et al.
Current Pharmaceutical Design|June 20, 2015
Off-Label Trazodone Prescription: Evidence, Benefits and RisksLetizia Bossini, Anna Coluccia, Ilaria Casolaro, et al.
Current Pharmaceutical Design|August 19, 2016
Editorial (Thematic Issue: Current and Perspective Therapeutic Strategies for Alzheimer's Disease)Antonio Palumbo Piccionello, Francesco Cappello
Current Pharmaceutical Design|March 17, 2018
TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic SyndromeMaria Luz Fernandez, Minu Sara Thomas, Bruno S Lemos, et al.
Pageof 1,066

Showing results (121-130 of 10,653) with videos related to

Sort By:
Pageof 1,066
Current Pharmaceutical Design|July 7, 2015
Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU EnvironmentCarlos J Madrid-Navarro, Rosa Sanchez-Galvez, Antonio Martinez-Nicolas, et al.
Current Pharmaceutical Design|July 7, 2015
Disruption of Circadian Rhythms in Critical Illness - A Role of Hyperoxia-Induced Lung InjuryAlexander Czachor, Zachary Krueger, Young Cho, et al.
Current Pharmaceutical Design|July 7, 2015
Disruption of Circadian Rhythms and Sleep in Critical Illness and its Impact on Innate ImmunityViola Dengler, Kristin Westphalen, Michael Koeppen
Current Pharmaceutical Design|June 2, 2015
Multifunctional Delivery Systems for Advanced oral Uptake of Peptide/Protein DrugsJin Woo Park, Sun Jin Kim, Dong Sup Kwag, et al.
Current Pharmaceutical Design|June 6, 2015
Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?Bart A Ellenbroek, Bibinaz Ghiabi
Current Pharmaceutical Design|June 20, 2015
Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of Schizophrenia. Current Evidence and Future DirectionsMarine Mondino, Jerome Brunelin, Ulrich Palm, et al.
Current Pharmaceutical Design|June 20, 2015
Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous SystemGary Hulse, Erin Kelty, Sean Hood, et al.
Current Pharmaceutical Design|June 20, 2015
Off-Label Trazodone Prescription: Evidence, Benefits and RisksLetizia Bossini, Anna Coluccia, Ilaria Casolaro, et al.
Current Pharmaceutical Design|August 19, 2016
Editorial (Thematic Issue: Current and Perspective Therapeutic Strategies for Alzheimer's Disease)Antonio Palumbo Piccionello, Francesco Cappello
Current Pharmaceutical Design|March 17, 2018
TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic SyndromeMaria Luz Fernandez, Minu Sara Thomas, Bruno S Lemos, et al.
Pageof 1,066